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Abstract
Muscle tissue plays several important health functions . In ad-
dition to the important mechanical functions, it represents 
the biggest reserve of body proteins and it is also able to 
produce several myokines that are able to induce important 
beneficial effects, through the interaction with different or-
gans. The loss of muscle mass has a tremendous impact on 
health and it is not surprising that a great interest has raised 
on two degenerative, irreversible and unstoppable condi-
tions known as sarcopenia and cachexia. 
Sarcopenia, the age-related loss of muscle mass, is not a dis-
ease or a syndrome, it is not even a medical sign sometimes. 
Indeed, a general consensus among scientists does not exist 
regarding the definition and the identification criteria of this 
condition.
On the other hand, cachexia is a wasting syndrome charac-
terized by an uncontrolled and unstoppable loss of muscle 
mass, associated with fatigue and weakness. It is often associ-
ated with a disease like cancer, AIDS, Chronic Obstructive Pul-
monary Disease (COPD), multiple sclerosis, tuberculosis etc.
Given the complexity of these muscle conditions and consid-
ering that during aging and cancer there is an increased risk 
of comorbidities, regular physical activity might be a crucial 
point to be carefully evaluated on a single patient basis.
The aim of this review is to highlight the impact on society 
and the etiology of sarcopenia and cancer cachexia, with par-
ticular regard to the role played by physical activity in pre-
venting and counteracting these muscle-wasting conditions, 
focusing attention also on the limitation factors that must be 
considered during the prescription of physical activity to sar-
copenic and cachectic patients.  
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Sažetak
Mišićno tkivo ima nekoliko važnih uloga po ljudsko zdravlje. 
Pored značajne mehaničke funkcije, ono predstavlja i najveći 
depo telesnih proteina. Osim toga, proizvodi i nekoliko mi-
okina koji su, kroz interakcije sa drugim organima, u stanju 
da indukuju veoma bitne efekte. Gubitak mišićne mase ima 
izuzetan uticaj na zdravlje i ne iznenađuje činjenica da se sve 
više pažnje obraća na dva degenerativna, ireverzibilna i neza-
ustavljiva stanja, poznatija kao sarkopenija i kaheksija.
Sarkopenija, starosno zavisan gubitak mišićne mase, nije ni 
bolest ni sindrom, čak nekada nije ni medicinski znak. Kon-
senzus naučnika zapravo nije utemeljio preciznu definiciju, 
kao ni kriterijume u vezi sa ovim stanjem.
S druge strane, kaheksija predstavlja sindrom gubitka i karak-
teriše je nekontrolisan i nezaustavljiv gubitak mišićne mase, 
povezan sa umorom i slabošću. Često je povezana sa bolesti-
ma kao što su sindrom stečene imunodeficijencije (fr. syndro-
me d'immunodéficience acquise, SIDA), hronična opstruktivna 
bolest pluća (HOBP), multipla skleroza, tuberkuloza itd.
Imajući u vidu kompleksnost ovih stanja povezanih sa mišić-
nom masom, kao i činjenicu da je tokom starenja i u slučaju 
karcinoma povećan rizik od komorbiditeta, smatra se da re-
dovna fizička aktivnost može da ima krucijalnu ulogu zbog 
koje bi je trebalo pažljivo oceniti, uzimajući u obzir svakog 
pacijenta pojedinačno.
Cilj ovog preglednog rada je da se naglase uticaj sarkopenije na 
društvo, kao i etiologija sarkopenije i kaheksije, koja je povezana 
sa rakom. Poseban akcenat će biti stavljen na ulogu koju fizička 
aktivnost može da ima u prevenciji i suzbijanju navedenih stanja 
(povezanih sa gubitkom mišićne mase), usredsređujući se i na 
faktore ograničenja koji se moraju uzeti u obzir prilikom propisi-
vanja fizičke aktivnosti pacijentima sa sarkopenijom i kaheksijom.
Ključne reči: sarkopenija, kaheksija, mišićno tkivo, gubitak 
mišićne mase, fizička aktivnost, starenje, karcinom
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Introduction
The muscle mass represents the biggest reserve of body 
proteins; it plays different mechanical functions (move-
ment, maintaining posture, breathing etc.) and can be 
considered, to all-purposes, a secretory organ (1). Inter-
estingly, skeletal muscle produces different cytokines and 
peptides classified as “myokines” which are able to com-
municate with several organs simultaneously and to pro-
duce different benefits for health. Indeed, myokines exert 
either autocrine, endocrine or paracrine effects and their 
production is strongly associated with muscle mass and 
muscle contraction (2).
As human body ages, there is a gradual decrease in muscle 
mass. This age-related loss of contractile tissue is a serious 
threat for health and it is associated with a risk of adverse 
outcomes such as frailty, disability, chronic diseases and 
death (3). Given the tremendous impact on health, a great 
interest has raised on two degenerative, irreversible and 
unstoppable conditions known as sarcopenia and cachexia. 
Sarcopenia is a term introduced in 1988, by Irwin Rosen-
berg and means: “flesh poverty” (4). This age-related loss 
of skeletal muscle starts early in adulthood (approximate-
ly at the age of 20) (5), accelerating after the age of 65 with 
more than 1% of muscle mass loss per year (6). Moreover, 
it is often related to other conditions as dynapenia (loss 
of muscle strength and power associated with a reduced 
movement capability) and cachexia (3). Sarcopenia is 
not a disease or a syndrome, it is not even a medical sign 
sometimes. Indeed, it is difficult for physicians to deter-
mine whether the loss of muscle mass is physiological 
rather than pathological (3). In 2009, numerous scientif-
ic societies such as the European Geriatric Medicine, the 
European Society for Clinical Nutrition and Metabolism, 
the International Association of Gerontology and Geriat-
rics-European Region and the International Association 
of Nutrition and Aging, challenged their efforts to form 
an European group to get a practical clinical definition 
and a diagnostic criteria for sarcopenia forming The Eu-
ropean Working Group on Sarcopenia (EWGSOP). As 
explained in the next section, EWGSOP developed a clin-
ical definition and consensus diagnostic criteria for  the 
age-related sarcopenia, using both low muscle mass and 
low muscle functions (strength or performance) (7). 
On the other hand, cachexia is a wasting syndrome, char-
acterized by an uncontrolled and unstoppable loss of 
muscle mass, associated with fatigue and weakness. This 
condition is seen in patients with AIDS, Chronic Ob-
structive Pulmonary Disease (COPD), multiple sclerosis, 
tuberculosis and cancer (8). It is possible to identify three 
different stages of clinical relevance for cancer cachexia: 
pre-cachexia, cachexia and refractory cachexia (9). Pa-
tients with an involuntary loss of body weight of 5% in 6 
months or with a body mass index lower than 20 kg/m2 
are classified as having cachexia. In pre-cachexia, some 
symptoms (anorexia and impaired glucose tolerance) can 
accompany an involuntary loss of body weight lower than 
5% in 6 months. Refractory cachexia is the last stage of 
this condition and is characterized by an intense catabo-
lism, poor performance status and a life expectancy of a 
few months (10).
Currently, there are limited options to counteract the ef-
fects of muscle tissue loss as a part of aging or a disease 
process, except for lifestyle therapies like healthy nutri-
tion and exercise training. The aim of this review is to 
highlight the impact on society and the etiology of sarco-
penia and cancer cachexia with particular regard to the 
role played by physical activity, in preventing and coun-
teracting these muscle-wasting conditions.
Epidemiology of sarcopenia
and cancer cachexia
Despite the fact that the clinical definition and consensus 
about diagnostic criteria for age-related sarcopenia have 
been identified (7), it is still complicated to estimate the 
actual prevalence of sarcopenia and its impact on public 
health (11). Clear examples are presented in two different 
studies provided by Batsis et al. (12) and Bijlsma et al. (13), 
which compare the prevalence of sarcopenia using differ-
ent definitions and diagnostic parameters. In particular, 
Batsis and colleagues found that sarcopenia ranges from 
4.4% to 94% across definitions, while Bijlsma and collab-
orators, applying different diagnostic criteria to different 
age categories, found differences that range from 0% to 
31.2% in the 60-69 years group and from 0% to 45.2% 
in the over 70 years category. In its definition, EWGSOP 
integrates the loss of muscle mass, the loss of muscle 
strength and the loss of physical functions to identify the 
presence of sarcopenia, suggesting to adopt two standard 
deviations below the mean value of healthy young adults, 
as cut-off point for each field. According to this definition, 
at the World Congress on Osteoporosis, Osteoarthritis 
and Musculoskeletal Diseases, a research group from the 
University of Liège (Belgium) revealed dramatic numbers 
about the prevalence of sarcopenia in Europe, providing 
also some interesting projections. In 2016, the European 
citizens affected by sarcopenia there are 10 869 527 (11.1% 
of older population) and this number will tend to the in-
crease of 72.4%, reaching a total of 18 735 173 sarcopenic 
people in 2045 (12.9% of older population) (14).
Similarly to sarcopenia, cachexia, internationally recog-
nized as a complex “multifactorial syndrome defined by 
an ongoing loss of skeletal muscle mass (with or without 
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loss of fat mass) that cannot be fully reversed by conven-
tional nutritional support and leads to progressive func-
tional impairment” (9). Therefore, in agreement with this 
definition, epidemiological evidences show that cachexia 
affects 50% of cancer patients with a dramatic impact on 
quality of life, reducing the response to chemotherapy 
and even leading to death. In fact, it has been estimated 
that during cancer, more than 20% of patients die because 
of cachexia (15). Interestingly, the incidence of weight 
loss vary greatly according to the tumor site: the greatest 
weight loss was seen among patients with solid tumors 
(e.g. gastric, pancreatic, lung, colorectal, head and neck) 
(16). In particular, those patients with upper gastrointes-
tinal and lung cancer are more predisposed to this con-
dition with a prevalence of cachexia up to 80% and 60% 
respectively (17). Furthermore, patients with prostate 
or colon cancer experience cachexia in 50% of the cases 
while those with breast cancer or acute leukemia experi-
ence cachexia in 30% of cases (18).
Etiology of sarcopenia and cancer cachexia 
Sarcopenia is characterized by a decline in muscle mass 
with aging, where the muscle fibers are substituted by 
non-contractile tissue such as intramuscular fat and con-
nective tissue (19).  Although their relative contribution is 
still unknown, there are multitude of concomitant “inter-
nal” and “external” causes that could lead to this altered 
muscle mass condition (Figure 1). 
With regard to internal processes, the most important 
seems to be a reduced anabolic hormone production and 
sensitivity: in fact, aging is associated with lower Insu-
lin-like Growth Factor 1 (IGF-1), insulin resistance and 
testosterone levels, as well as a reduced sensitivity of their 
targets (20). Indeed, it is known that these hormones 
are potent activators of Protein kinase B (Akt) signaling 
pathway, resulting in increased production and decreased 
degradation of muscle proteins, by inhibition of the Fork-
head box (FoxO) pathway. Moreover, testosterone activity 
affects skeletal muscle tissue growth and differentiation 
through myoblast stimulation, inhibition of myostatin 
and satellite cells renewal (21).  In addition, the increase of 
apoptotic activities in myofibers, the increase of pro-in-
flammatory cytokines, the changes of muscle mitochon-
drial functions and the accumulation of free radicals, as 
well as the decline in the number of motor neurons (in 
particular of alpha-motor neurons) and a reduction of 
synaptic vesicles are all important contributors of  muscle 
wasting in sarcopenia. (6, 22). Among external influenc-
es, those that could be able to drive the pathophysiologi-
cal changes leading to muscle loss are “disuse or immo-
bility” and a deficient intake of energy and proteins. It is 
important to consider that older people are among the 
most sedentary and physically inactive segment of society 
(23). As people age, they become less active and this plac-
es them inside a tremendous vicious cycle (figure 2) in 
which there is not only an increased loss of muscle mass 
but also an increased risk of disability, morbidities and 
premature death (24).
Similarly to sarcopenia, even the cachexia syndrome 
shows a systemic inflammation state (25). In fact, an im-
balance between pro-inflammatory and anti-inflammato-
ry cytokines is currently believed to contribute to cachex-
ia (26). Moreover, other pathophysiological mechanisms 
Figure 1. Sarcopenia is a complex condition mediated by different causes that interact to generate muscle wasting.
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are shared with sarcopenia, such as the down-regulation 
of anabolic factors/pathways including IGF-1, androgens 
and satellite cells proliferation, as well as an increase in 
catabolic pathways such as apoptosis, autophagy and mi-
tochondrial dysfunction (mitophagy) (6, 20, 21). Cachexia 
can also result from a reduced availability of nutrients; 
in fact, it is noteworthy that, while not all malnourished 
patients are cachectic, all cachectic patients are invariably 
malnourished. Therefore, together with the inflammato-
ry imbalance, this state of malnutrition leads eventually 
to accumulation of damaging free radical that are known 
as reactive oxygen species (ROS), such as hydroxyl rad-
icals, superoxide radicals and others (27). Reactive oxy-
gen species are chemically reactive molecules containing 
oxygen with an unpaired electron and this conformation 
gives them the possibility to interact with different other 
molecules (28). These molecules are considered regula-
tors of cellular functions during inflammatory response, 
but an over-accumulation beyond a certain threshold, 
can have different detrimental effects (29). ROS activity 
can last for days in absence of an adequate antioxidant 
response and these species can move outside the cell and 
react with other tissues provoking oxidative stress (30). 
To date, oxidative stress plays a key role in tissue degen-
eration and, consequently, in systems dysfunctions; ROS 
accumulation seems to be the potential trigger of many 
chronic diseases (31).
Exercise as a tool to counteract
sarcopenia and cancer-related cachexia
Sarcopenia and cachexia are complex conditions in which 
many systems are involved simultaneously. Hormon-
al and drugs supplementation are palliative solutions to 
counteract the effects of these two degenerative pathways 
(32, 33). On the other hand, physical activity seems to 
be the most effective treatment in preventing and coun-
teracting age and cancer-related muscle tissue loss. It is 
widely known that physical activity is a panacea able to 
prevent and treat multiple age-related diseases (34) even 
in elders that have been inactive for the majority of their 
life (35). In the light of this, many studies have focused 
their attention on the effects of physical activity on pre-
vention and treatment of sarcopenia, but only few studies 
have investigated the impact of exercise training on pre-
cachectic and cachectic patients (36).
Physical activity produces many healthful benefits but, 
at the same time, it carries some risks: these types of in-
terventions, in particular in elderly, must be carried out 
considering the patients profile and must be supervised 
Figure 2: Entering in the physical inactivity vicious cycle has a 
tremendous impact on people quality of  life. It provokes sev-
eral detrimental effects and could leads to disability and death. 
Figure 3: Cachexia is a multifactorial process determined by different bio-functional alterations of homeostasis.
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by experts of the field and started after a careful medi-
cal screening. Prescribing physical activity to cancer pa-
tients is an extremely delicate process. Physicians must 
consider the complete medical case and the relative lim-
itations associated with the pathology and the therapy. 
As for example, anemia is an important limiting factor 
to the participation in physical activities. Indeed, the 
concomitant presence of this condition, which affect one 
third of cancer patients at diagnosis (37), when partici-
pating in physical activities could be both dangerous and 
deleterious for patients, as demonstrated by Argilés and 
colleagues (38) in tumor bearing mice, where the health 
conditions of anemic animals worsen after exercise. It is, 
therefore, advisable to immediately interrupt any extra 
activity different from daily life, when anemia is present 
(38, 39). Despite anemia which is an important limitation 
factor to the participation in regular physical activity in 
cancer patients, there are many other aspects that must 
be taken into account during exercise prescription. It is 
necessary to consider that patients with compromised 
immune functions, that complete a bone marrow trans-
plant, should avoid public places for at least 1 year after 
the transplantation and that the exposure to chlorine 
(swimming pool activities) after radioactive treatments 
could cause skin irritations (39).
In the end, it is important to consider that cachectic pa-
tients are overexposed to the risk of muscle dislodgment 
and an adequate warm-up and load progression are fun-
damental aspects of exercise prescription (39). Notewor-
thy, during chemotherapy and radiation, most patients 
feel a general sense of fatigue. This tiredness does not 
get better with rest, but at the same time could severely 
limit the participation in physical activity programs. The 
NCCN Clinical Practice Guidelines in Oncology (NCCN 
Guidelines®) for Cancer-Related Fatigue, suggest to physi-
cians and sport scientists to start slowly and progressive-
ly increase the intensity and duration of the exercises, to 
avoid injuries and dropout. 
A clear consensus regarding exercise recommendations 
for sarcopenic and cachectic patients do not exist. Any-
way, the American College of Sport Medicine (ACSM) 
and the American Heart Association (AHA) provide 
some guidelines for adults over 65 years of age that could 
be applied, with the proper precautions, to both sarcope-
nic and cachectic groups (40).
To counteract muscle wasting and, in particular, the loss 
of muscle functions associated with sarcopenia and ca-
chexia, ACSM and AHA suggest to integrate aerobic, 
resistance and flexibility training to routine activities of 
daily living of light or moderate intensity (e.g., self-care, 
cooking, casual walking or shopping etc.).
Aerobic training is any type of exercise that stimulates 
and strengthens the heart and lungs functions and im-
proves the body’s oxygen utilization. It is an important 
physiological stimulus able to induce many functional 
improvements extending life expectancy, reducing the 
risk of many chronic disorders and orchestrating numer-
ous adaptation in skeletal muscles (see below) (41; 42). 
During this type of activities, such as walking, jogging 
and running, tissue metabolism uses oxygen at a rate at 
which the cardio respiratory system can replenish it in 
the working muscles.
ACSM and AHA recommend the participation in mod-
erate-intensity aerobic training for a minimum of 30 
minutes on five days each week (150 min/week) or vig-
orous-intensity aerobic activity for a minimum of 20 
minutes on three days each week (60 min/week). Mod-
erate-intensity aerobic activities produce a great increase 
in heart rate and breathing and, on a scale where 0 rep-
resents “no load” and 10 an “all-out effort”, they represent 
a 5 or 6.  On the other hand, vigorous intensity activities 
produce a large increase in heart rate and breathing and, 
on the same scale, represent 7 or 8 (43).
Several studies have shown the effectiveness of resistance 
training in improving muscle mass and functions. This 
type of training is “a form of physical activity designed 
to improve muscular fitness by exercising a muscle or a 
muscle group against external resistance” (44). ACSM and 
AHA recommend, at least, two resistance-training ses-
sions per week (to be performed in non-consecutive days 
to ensure enough recovery time) in which all the six major 
muscle groups must be involved (chest, shoulders, arms, 
back, abdomen and legs). Different types of resistance 
training are described in literature, differing from each 
other regarding the intensity, the number of repetitions 
and the velocity of execution. ACSM and AHA suggest 
a slow-moderate intensity resistance training performed 
with a resistance (weight) that allows 10 to 15 repetitions 
at 65-70% of one repetition maximum (1RM), performing 
the concentric and eccentric phase in 2-3 seconds for each 
muscle contraction. This type of training is effective in 
increasing muscle strength but seems to be less effective 
in increasing muscle mass and power (43, 45, 46). In order 
to allow the proper progression, ACSM recommend to 
progressively increase the load according to the improve-
ments made by the patients and in consideration of spe-
cific strength tests that must be performed frequently and 
constantly to estimate the 1 Repetition Maximum (1RM; 
index of maximal strength).
The loss of the muscle power, closely associated with 
muscle wasting, is a significant predictor of performing 
activities of daily living (i.e., getting dressed, cooking, 
carrying groceries, climbing stairs, etc.). To train muscle 
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power, the exercise protocols shall include 3 to 6 repeti-
tions with an intensity higher than 80% of 1RM with a 
concentric phase performed as quickly as possible and an 
eccentric phase duration of approximately 2 seconds for 
each muscle contraction (45).
Finally, in order to reduce the risk of falls and subsequent 
debilitating injuries, ACSM and AHA suggest to integrate 
aerobic and resistance training with exercises focus on 
maintaining and improving balance and flexibility every 
day for at least 10 minutes (43).
Different molecular adaptations in multiple tissues un-
derline the benefits determined by physical activity in 
both sarcopenic and cachectic subjects. Various signals, 
including Ca2+ and adenosine monophosphate (AMP), 
are activated by aerobic exercise. These signals activate in-
tracellular pathways such as calcium/calmodulin-depen-
dent protein kinase (CaMK) and AMP-activated protein 
kinase (AMPK) that lead to an increase of mitochondrial 
genes activity (47). One of the most important regulators 
of mitochondrial biogenesis is the peroxisome prolifera-
tion activated receptor gamma co-activator -1α (PGC-1α) 
whose production is strongly induced by aerobic exer-
cise (48, 49). Therefore, executing aerobic activities, the 
improved muscle mitochondrial content and efficiency, 
improves the capacity to cope with oxidative stress and 
optimize exercise capacity (50). Indeed, this type of exer-
cise might not only counteract the reduction of oxidative 
capacity found in experimental cachexia (51), but it also 
stimulates the oxidative metabolism to prevent hyper-
lipidemia and, consequently, ameliorate the insulin re-
sistance. Interestingly, aerobic exercise can also increase 
the skeletal muscle insulin sensitivity (52) increasing 
glucose transporters (GLUT 1-4) expression and activity. 
Although the mechanisms behind are still unknown, it 
seems that this increased insulin sensitivity could reduce 
the muscle protein breakdown (53).
On the other side, an intriguing hypothesis about the 
mechanism of action of resistance training foresees that 
this type of training is able to exert its effect on tran-
scriptome and, in particular, Raue and colleagues (54) 
found that 661 genes were responsive to resistance exer-
cise and that they correlated with the increase in whole 
muscle size and strength. In addition, it has been widely 
demonstrated that resistance training enhances the rate 
of mixed muscle protein synthesis in older participants 
guarantying an effective muscle proteins turnover and 
reducing muscle wasting (55, 56, 57).  Moreover, several 
studies agree with the idea that physical activity can ex-
erts important functions against many other age-related 
markers improving the general adaptive response of spe-
cific anti-oxidant and stress proteins (58).
Conclusion
It is known that weight and muscle loss are associated with 
frailty, loss of independence and increased mortality. The 
population most affected by these wasting syndromes and 
their unfavorable consequences are elderly and cancer pa-
tients. Despite  many efforts carried out by the scientific 
community to identify proper tests (i.e. postural balance, 
gait speed, handgrip strength, leg extension, measures of 
body composition and global physical function), to date, 
sarcopenia and cachexia in the majority of patients are 
not identified until the disease is advanced. In particular, 
cachexia is a condition that may be present in the early 
stages of tumor growth and sometimes before any signs 
or symptoms of malignancy (59). Currently, there are 
limited options to counteract the effects of muscle mass 
loss as a part of aging or a disease process, except for life-
style therapies like physical activity.
Given the complexity of these muscle conditions and 
considering that during aging and cancer there is an in-
creased risk of comorbidities, the exercise dose should be 
a crucial point to be carefully evaluated on a single pa-
tient basis.
In this review, we have presented some of the beneficial 
effects that physical activity could produce in counter-
acting sarcopenia and cancer cachexia. Indeed, physical 
activity seems to be the most effective method to treat 
these degenerative conditions, producing many benefits 
with very few side effects. Therefore, considering both 
the maintenance of muscle mass and the aforementioned 
molecular effects induced by different motor intervention 
protocols, a combination of aerobic and resistance exer-
cise rather than only one of them appears to be preferred. 
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